Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors

Status Active, not recruiting

Clinical Trial Summary

This study will evaluate how Gallium-68 Pentixafor is distributed in neuroendocrine tumor patients and if that distribution is consistent through repeated scans. This is an RDRC study - as such, the images obtained for this study cannot be used clinically or shared with treating oncologists.

Clinical Trial Description

High grade neuroendocrine tumors often do not express somatostatin (sstr) receptors but often express the CXCR4 receptor. The CXCR4 receptor is a marker of poorly differentiated cells. Pentixafor is a peptide that targets these CXCR4 receptors. By combining it with gallium-68, a radionuclide, pentixafor can then be evaluated as an imaging agent to detect high-grade neuroendocrine tumors. [68Ga]Pentixafor is a radio-labelled imaging agent used for positron emission tomography (PET). The dose is small, known as a tracer dose. It is designed to capture information about the body and how the body is working without interfering or causing an effect. The goal of this study is to evaluate how the [68Ga]Pentixafor is distributed through the body after injection and how it is taken up by the organs of the body. The study will also examine if the imaging is reproducible to determine if the PET images show the same uptake of the study drug across different scans. This study is an RDRC study - the equivalent to a phase 0 study. The [68Ga]Pentixafor has not been shown to target tumors; specificity and sensitivity have not been established. For this reason, images obtained for this study cannot be used clinically or shared with treating oncologists. ;

Study Design

Related Conditions & MeSH terms

Neuroendocrine Tumors

Clinical Trial Details

NCT number	NCT03335670
Study type	Interventional
Source	University of Iowa
Contact
Status	Active, not recruiting
Phase	Early Phase 1
Start date	November 3, 2017
Completion date	December 31, 2027

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01218555` - Study of Everolimus (RAD001) in Combination With Lenalidomide	Phase 1
Recruiting	`NCT03412877` - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer	Phase 2
Withdrawn	`NCT04614766` - A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors	Phase 1/Phase 2
Recruiting	`NCT05556473` - F-Tryptophan PET/CT in Human Cancers	Phase 1
Completed	`NCT03273712` - Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)	Phase 2
Recruiting	`NCT05636618` - Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors	Phase 1/Phase 2
Terminated	`NCT03986593` - Cryoablation of Bone Metastases From Endocrine Tumors	N/A
Recruiting	`NCT04584008` - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics	N/A
Completed	`NCT02815969` - The Indol Profile; Exploring the Metabolic Profile of Neuroendocrine Tumors
Completed	`NCT02441062` - Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors	Phase 2
Active, not recruiting	`NCT02174549` - Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer	Phase 1/Phase 2
Completed	`NCT02134639` - PET-CT Imaging of Neuro-endocrine Tumors and Preliminary Clinical Evaluation	N/A
Completed	`NCT02132468` - A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers	Phase 2
Recruiting	`NCT01201096` - Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors (NEO-LEBE)	N/A
Terminated	`NCT01163526` - Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies	N/A
Completed	`NCT01099228` - Combination Targeted Radiotherapy in Neuroendocrine Tumors	N/A
Completed	`NCT00171873` - Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut	Phase 3
Active, not recruiting	`NCT05077384` - Open-label Study of Surufatinib in Japanese Patients	Phase 1/Phase 2
Active, not recruiting	`NCT04544098` - Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver	Early Phase 1
Active, not recruiting	`NCT02736500` - Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors	Phase 1/Phase 2